Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial

Authors

Linda M Liau, University of California, Los Angeles
Jian L Campian, Washington University School of Medicine in St. Louis
George Ansstas, Washington University School of Medicine in St. Louis
et al.

Journal

JAMA Oncology

Publication Date

1-1-2023

Volume

9

Issue

1

First Page

112

Last Page

121

Document Type

Open Access Publication

DOI

10.1001/jamaoncol.2022.5370

Rights and Permissions

Liau LM, Ashkan K, Brem S, et al. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial. JAMA Oncol. 2023;9(1):112–121. doi:10.1001/jamaoncol.2022.5370. This is an open access article distributed under the terms of the CC-BY-NC-ND License. © 2022 Liau LM et al. JAMA Oncology.

Recommended Citation

Liau, Linda M; Campian, Jian L; Ansstas, George; and et al., "Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial." JAMA Oncology. 9, 1. 112 - 121. (2023).
https://digitalcommons.wustl.edu/oa_4/4554

Additional Links

Supplemental material is available for this article at publisher site.